Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
This simplified the trial design but raises legitimate questions about whether weight-based dosing might improve outcomes
Standard escalation follows: 0.25mg weeks 1-4, 0.5mg weeks 5-8, 1.0mg weeks 9-12, with potential further increases to 1.7mg or 2.4mg based on response
The scientists commented that: regulation of the pro-inflammatory milieu of the ischemic retina can be enhanced by ARA290 and may be a useful [research agent] to ECFC-based cell [procedures] for ischemic retinopathies
Dosage Protocols and Administration Guidelines Finding an appropriate dose for research requires reviewing available data, considering research goals, and accounting for injury type and severity
